EpiVax, Inc. - Informatics and Immunology
  • Our Company
    • Company Overview
    • Corporate Responsibility
    • Mission, Vision & Values
    • Team
    • Careers
    • Contact Us
  • Pipeline
    • Pipeline Overview
    • BioDefense Vaccines
    • Tregitope: Immunomodulation Power Tool
    • Deimmunization Projects
  • Vaccine Services
    • Vaccine Services
    • iVAX: Web-based Vaccine Design
    • PreVAX Analysis
    • EpiCC
  • Immunogenicity Assessment
    • Immunogenicity Assessment Overview
    • ISPRI Web-based Immunogenicity Assessment
    • PreDeFT Analysis
    • High Throughput Immunogenicity Analysis
    • PANDA Screening
    • ISPRI for Host Cell Proteins
    • Deimmunization
    • Trusted Expert Advice (TEA) Consulting Services
  • Lab Services
    • Lab Services Overview
    • HLA Binding Assays
    • T Cell Assays
  • Press Room
    • Press Room
    • Events
      • Webinars
    • Publication & Poster Search
    • Client Testimonials
    • Thinking Out Loud (Blog)
    • Recipes For Success (Podcast)
  • Contact Us
Select Page
Immune camouflage: Relevance to vaccines and human immunology

Immune camouflage: Relevance to vaccines and human immunology

by Annie De Groot | Jan 13, 2020

De Groot et al. – 2014 – Immune camouflage Relevance to vaccines and human immunology
An Integrated Genomic and Immunoinformatic Approach to H. pylori Vaccine Design. 2011

An Integrated Genomic and Immunoinformatic Approach to H. pylori Vaccine Design. 2011

by epivax3 | Oct 22, 2016

Immunome Research. Vol 7, No 2 (2011). https://immunome-research.net/journal/index.php/immunome.
Building Better Biotherapeutics and Vaccines by Design: EpiVax, Inc., an Immunology Company

Building Better Biotherapeutics and Vaccines by Design: EpiVax, Inc., an Immunology Company

by epivax3 | Oct 22, 2016

Rhode Island Medical Journal, February 2013. rimed.org/rimedicaljournal/2013-02/2013-02-19-bio-epivax.pdf
Universal H1N1 influenza vaccine development: Identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011

Universal H1N1 influenza vaccine development: Identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011

by epivax3 | Oct 22, 2016

Human Vaccines & Immunotherapeutics 2013; 9:1598 – 1607; PMID: 23846304; https://dx.doi.org/10.4161/hv.25598
Immunization with Cross-conserved H1N1 Influenza CD4+ T Cell Epitopes Lowers Viral Burden in HLA DR3 Transgenic Mice

Immunization with Cross-conserved H1N1 Influenza CD4+ T Cell Epitopes Lowers Viral Burden in HLA DR3 Transgenic Mice

by epivax3 | Oct 22, 2016

Hum Vaccin Immunother. 2013 Sep 17;9(10).
« Older Entries

Recent Posts

  • From Kyoto, with Love
  • EpiVax Turns 25!
  • Happy Valentine’s Day! And don’t argue with Chatbots!
  • ISPRI in silico Toolkit in the Literature
  • Platform shoes, Bellbottoms and #CrueltyFreeFDA!

Categories

  • EpiVax Immunoncology
  • Events
  • Featured
  • News
  • Recipes for Success – Vlog
  • Thinking Out Loud -Blog
  • Uncategorized
  • Webinars

Discover

  • Vaccine Services
  • Immunogenicity Assessment
  • Deimmunization
  • Lab Services
  • Pipeline

About

  • Our Company
  • Press Room
  • Events
  • Publication & Poster Search
  • Thinking Out Loud (Blog)
  • Contact Us

Connect

© 2023 EpiVax, Inc. – Informatics and Immunology, All rights reserved. Privacy Policy • 188 Valley Street, Suite 424, Providence, RI 02909 • ph: 401.272.2123 • fax: 401.272.7562